For example, the presence of mutations in the epidermal growth factor receptor (EGFR) gene qualifies NSCLC adenocarcinoma patients for targeted therapy with tyrosine kinase inhibitors (TKIs), leading to improved overall survival3, 4, 5, 6. This evidence concerns the gene EGFR and adenocarcinoma.